Clinical Trial Update: Sorafenib Plus Toripalimab for Unresectable HCC With Portal Vein Tumor Thrombus [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update on combination therapy of sorafenib and toripalimab for unresectable hepatocellular carcinoma with portal vein tumor thrombus (Phase 1/Pha…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Sorafenib (Sorafenib)
• Toripalimab (Toripalimab)

Snippet

Sponsor: Sichuan University | Conditions: Unresectable Hepatocellular Cancer, Portal Vein Tumor Thrombus | Phase 1, Phase 2 | Status: UNKNOWN